BABimal Kumar Agrawal

Bimal Kumar Agrawal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bimal Kumar Agrawal has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Parminder Nain

    Department of Pharmacy Practice, CT Institute of Pharmaceutical Sciences, Shahpur, Jalandhar, Punjab 144020, India

    2 shared publications
  • Rajinder Singh

    Pancham Multi Special Hosp, Dept Med, Ludhiana, Punjab, India

    2 shared publications
  • Sanjana Mehta

    Maharishi Markandeshwar Coll Pharm Deemed Univ, Dept Pharm Practice, Mullana, Haryana, India

    2 shared publications
  • Akash Garg

    Department of Medicine, MM Institute of Medical Sciences and Research, Maharishi Markandeshwar Deemed to be University, Mullana, Haryana, India

    1 shared publication
  • Aman Bharti

    Assistant Professor, Department of Medicine, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India

    1 shared publication
  • Amit Mittal

    Professor and Head, Department of Radiology, Maharishi Markandeshwar, Deemed to be University, Ambala, Haryana, India

    1 shared publication

Latest Publications

  • Open Access

    Limited Therapeutic Options in blaNDM and blaOXA-48 producing Carbapenem-resistant Klebsiella pneumoniae: Insights from a Cross-sectional Study

    by Rohit Kumar, Narinder Kaur, Harit Kumar, Bimal Kumar Agrawal, Rosy Bala, Shubham Chauhan, Sahil Kumar

    Carbapenem-resistant K. pneumoniae (CRKP), listed in the WHO 2024 priority, hydrolyzes β-lactam antibiotics, especially carbapenems, posing a significant challenge. Carbapenems are the last resort antibiotics for severe Gram-negative infections and are associated with increased mortality in ICUs and IPDs. This cross-sectional study at a tertiary hospital (April 2023-December 2024) included 375 multidrug-resistant (MDR) K. pneumoniae isolates with ertapenem MIC ≥8 µg/mL. Carbapenemase genes were detected via conventional PCR. Bivariate analysis examined clinical correlations, while MIC50/90 assessed resistance. The most common carbapenemase genes were blaNDM (48.26%) and blaOXA-48 (37.86%), followed by blaKPC (13.6%). Co-occurrence of genes was also reported. Twelve of seventeen clinical variables were significantly associated with gene presence (p < 0.05). Ertapenem, imipenem, and meropenem had MIC50/90 ≥8 µg/mL, indicating high resistance. Tigecycline showed better sensitivity, with MIC50/90 of 0.5/2 µg/mL (blaNDM) and 2/2 µg/mL (blaOXA-48). Fosfomycin MIC90 in blaOXA-48 isolates ranged up to 256 µg/mL. The study highlights high blaNDM and blaOXA-48 prevalence, their clinical associations, and limited therapeutic options. Tigecycline remains most effective in vitro, but pharmacokinetic concerns exist. These findings emphasize the need for antimicrobial stewardship and molecular surveillance.


  • Vitamin D with Calcium Supplementation Managing Glycemic Control with HbA1c and Improve Quality of Life in Patients with Diabetes

    by Sanjana Mehta, Parminder Nain, Bimal K. Agrawal, Rajinder Pal Singh

    Objectives: This study evaluates the effect of vitamin D with calcium supplementation on glycemic control and quality of life (QoL) in patients with diabetes. Materials and Methods: A prospective, observational, open-label randomized, controlled study was conducted on 150 type-2 patients with diabetes. A total number of patients were divided into three groups (n= 50 in each group) i.e. group 1 (patient on oral hypoglycemic agents), group 2 (oral hypoglycemic agents with vitamin D 60.000 IU/week), and group 3 (oral hypoglycemic agents, vitamin D 60.000 IU/week along with daily calcium of 1.000 mg/day). Biochemical estimation of fasting/random blood glucose (RBG), hemoglobin A1c (HbA1c), serum insulin and patient's QoL were analyzed using modified diabetes QoL (MDQoL)-17 questionnaire after 12 weeks of treatment. Data were analyzed using a student t-test (paired t-test) Results: The majority of the patients were male (more than 50%) with an average age of 50 +/- 6 years having a diabetic history of more than 10 years and HbA1c level >10% in all three groups. After 12 weeks supplementation, the mean value of vitamin D was 25.73 +/- 6.2 ng/mL, 29.98 +/- 5.3 ng/mL and 62.71 +/- 7.8* ng/mL in groups 1, 2, and 3, respectively (p<0.05) compared to baseline. A change in the mean value of HbA1c, in group 2 (14.64 +/- 3.48 to 13.99 +/- 3.16%) and group 3 (14.05 +/- 2.65 to 12.04 +/- 2.21%) was also seen at the end of the study. Moreover, patients showed a positive effect of vitamin D with calcium in group 3 with increased MDQoL, 30% of patients were in more than 70 score range. Conclusion: The result of the study indicates that vitamin D supplementation with calcium significantly controlled or reduced HbA1c; fasting and RBG levels moreover improve QoL in type-2 patients with diabetes. It suggests that this combination can be considered a therapeutic supplement along with a primarily used anti-diabetic regimen.


  • Open Access

    Effectiveness of Empagliflozin With Vitamin D Supplementation in Peripheral Neuropathy in Type 2 Diabetic Patients

    by Sanjana Mehta, Parminder Nain, Bimal K. Agrawal, Rajinder P. Singh, Jaspreet Kaur, Sabyasachi Maity, Aniruddha Bhattarcharjee, Jagannadha Peela, Shreya Nauhria, Samal Nauhria

    Background: Neuropathy is the most prevalent broad-spectrum microvascular complication of diabetes. The present study aims to evaluate the effect of empagliflozin with vitamin D supplementation on diabetic peripheral neuropathy. Methods: A prospective, randomized, controlled study was conducted for six months including 150 type 2 diabetic patients, divided into three groups (n=50/group): Group 1, patients on oral hypoglycemic agents; Group 2, patients on empagliflozin and Group 3, patients on empagliflozin with vitamin D. Biochemical parameters were estimated for outcome measurements and patients’ neuropathic pain was analysed using Douleur Neuropathique 4 Questions, Neuropathic Pain Symptom Inventory and Ipswich Touch the toes test questionnaire. Data were analysed using a one-way analysis of variance. Results: Diabetic neuropathy in males was more prevalent (more than 50%) as compared to females in all three groups, with an average age of 50±6 years, along with a diabetic history of 15±4.5 years and a glycated hemoglobin A1C (HbA1C) level of >10%. The mean value of serum vitamin D level significantly increased by 64.7% (19±5 to 54±8 ng/mL; p<0.05). A remarkable decrease (by 17.4%) from baseline in the HbA1C level was observed after six months of treatment only in Group 3, whereas in other groups (1 and 2), there was a non-significant decrease in HbA1C levels when compared to baseline. Moreover, a significant improvement in neuropathic condition was seen only in Group 3. Conclusion: The results indicated that empagliflozin with vitamin D supplementation significantly controlled or reduced HbA1C and improved diabetic neuropathic symptoms in patients. It is suggested that this combination can be considered as the primary therapeutic approach for neuropathic complications in diabetic patients.


  • Open Access

    Poncet’s Disease Revisited

    by Mini Bhatnagar, Bimal K Agrawal, C Srivatsa, Dil Preet Reehal, Jaskaran Bazad

    Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.

  • Open Access

    Oxidative Stress, Neuroinflammation, and NADPH Oxidase: Implications in the Pathogenesis and Treatment of Alzheimer’s Disease

    by Upasana Ganguly, Upinder Kaur, Sankha Shubhra Chakrabarti, Priyanka Sharma, Bimal Kumar Agrawal, Luciano Saso, Sasanka Chakrabarti

    NADPH oxidase as an important source of intracellular reactive oxygen species (ROS) has gained enormous importance over the years, and the detailed structures of all the isoenzymes of the NADPH oxidase family and their regulation have been well explored. The enzyme has been implicated in a variety of diseases including neurodegenerative diseases. The present brief review examines the body of evidence that links NADPH oxidase with the genesis and progression of Alzheimer’s disease (AD). In short, evidence suggests that microglial activation and inflammatory response in the AD brain is associated with increased production of ROS by microglial NADPH oxidase. Along with other inflammatory mediators, ROS take part in neuronal degeneration and enhance the microglial activation process. The review also evaluates the current state of NADPH oxidase inhibitors as potential disease‐modifying agents for AD.


  • Open Access

    Psychological Impact among COVID-19 Positive Patients in a Tertiary Care Hospital: A Cross-sectional Study

    by Poonam Bharti, Bimal Kumar Agrawal, Parul Gupta, Mohit Singla, Ln Garg, Amit Mittal, Aman Bharti

    Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.

  • Open Access

    Kala Azar- Difficult Yet Diagnosable Entity

    by Barinder Kaur, Charu Batra Atreja, Bimal K. Agrawal